Karen Zaderej becomes AxoGen's CEO
This article was originally published in Clinica
Peripheral nerve regeneration specialist AxoGen has promoted Karen Zaderej to CEO. Ms Zaderej, who was previously chief operating officer, helped to develop and launch the company's Avance nerve graft, and the AxoGuard nerve connector and nerve protector. She has worked for Johnson & Johnson subsidiary Ethicon, and also started her own business, Zaderej Medical Consulting. Alachua, Florida-based AxoGen plans to expand into new markets and develop new products to treat peripheral nerve injuries. Ms Zaderej replaces the former CEO, Jamie Grooms, who will remain chairman of the board.